Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Work In Process: 2023-2025

Historic Work In Process for Iovance Biotherapeutics (IOVA) over the last 1 years, with Mar 2025 value amounting to $12.1 million.

  • Iovance Biotherapeutics' Work In Process rose 104.40% to $12.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $12.1 million, marking a year-over-year increase of 104.40%. This contributed to the annual value of $8.8 million for FY2024, which is 52.46% up from last year.
  • As of Q1 2025, Iovance Biotherapeutics' Work In Process stood at $12.1 million, which was up 37.91% from $8.8 million recorded in Q4 2024.
  • In the past 5 years, Iovance Biotherapeutics' Work In Process ranged from a high of $12.1 million in Q1 2025 and a low of $4.3 million during Q3 2023.
  • In the last 3 years, Iovance Biotherapeutics' Work In Process had a median value of $7.3 million in 2023 and averaged $7.6 million.
  • Data for Iovance Biotherapeutics' Work In Process shows a peak YoY skyrocketed of 104.40% (in 2025) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Work In Process (Quarterly) stood at $5.7 million in 2023, then soared by 52.46% to $8.8 million in 2024, then soared by 104.40% to $12.1 million in 2025.
  • Its Work In Process stands at $12.1 million for Q1 2025, versus $8.8 million for Q4 2024 and $5.9 million for Q1 2024.